Medivir Pulls Plug on HCV NS5A Program for Lack of Demand
With lead hepatitis C virus (HCV) candidate simeprevir (TMC435) nearing the finish line and two nucleotide (nuc) polymerase inhibitor candidates for HCV in its pipeline, Medivir AB pulled the plug on its NS5A inhibitor program, citing lack of market demand, difficulty meeting its development timetable and the desire to reallocate in-house resources.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST